Nucresiran vs Vutrisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Cardiomyopathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Cardiomyopathy pipeline
Nucresiran
Developed by Alnylam Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2030 · NCT07052903 (registry estimate)
No aligned efficacy figure on record for this race.
Vutrisiran · AMVUTTRA
Marketed by Alnylam Pharmaceuticals
NCT04153149 · Phase 3 · active, not recruiting
HELIOS-B randomised 655 patients with transthyretin amyloid cardiomyopathy to vutrisiran or placebo under quadruple masking. Both primary analyses of the clinical composite endpoint (all-cause death and recurrent cardiovascular events) were met: HR 0.718 (p=0.0118) in the overall population and HR 0.672 (p=0.0162) in the monotherapy subgroup.
Next expected readout: March 2028 · NCT06679946 (registry estimate)
Reported efficacy
Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population (Up to Month 36); Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy Subgroup (Up to Month 36): Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 (met)
Result source: NCT04153149
Results for Transthyretin Amyloidosis with Cardiomyopathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Cardiomyopathy.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Transthyretin Amyloidosis with Polyneuropathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline
Nucresiran
Developed by Alnylam Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07223203 (registry estimate)
No aligned efficacy figure on record for this race.
Vutrisiran · AMVUTTRA
Marketed by Alnylam Pharmaceuticals
NCT03759379 · Phase 3 · completed
This was a randomized but open-label study, and its primary comparison used 122 vutrisiran-treated participants versus 77 participants from an external APOLLO placebo group rather than a concurrent blinded placebo arm. The clinical primary endpoint, change in mNIS+7 at Month 9, favored vutrisiran and was statistically significant, but the lack of blinding and use of an external comparator limit the strength of the evidence.
Reported efficacy
Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) (met)
Result source: NCT03759379
Results for Transthyretin Amyloidosis with Polyneuropathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Polyneuropathy.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nucresiran's landscape · Vutrisiran's landscape